EpiDisease provides biomedical solutions, epigenetic diagnostic tools, and characterization of new epigenetic drugs.
EpiDisease has raised $2.1M in total funding. The most recent round was Grant. The last funding was announced in October 2026.
EpiDisease's investors include Centre for the Development of Industrial Technology (CDTI), Fundacion Botin.
EpiDisease is headquartered in Paterna, Spain.
EpiDisease provides biomedical solutions, epigenetic diagnostic tools, and characterization of new epigenetic drugs.
EpiDisease is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"EpiDisease — Funding & Investors." VCBacked, October 23, 2026, https://www.vcbacked.co/company/epidisease. Accessed November 3, 2026.
VCBacked. (2026). EpiDisease — Funding & Investors. Retrieved November 3, 2026, from https://www.vcbacked.co/company/epidisease
{{cite web |title=EpiDisease — Funding & Investors |url=https://www.vcbacked.co/company/epidisease |website=VCBacked |access-date=November 3, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at EpiDisease? Request a listing update